Aβ and tau levels in the blood or cerebrospinal fluid (CSF), neurodegeneration measured as brain atrophy in structural MRI, and metabolism (e.g., FDG PET) could inform more precisely the expected change in brain amyloid levels, and, in turn, amyloid PET could predict the expected progression on these biomarkers (Bossa et al., 2022; Bossa and Sahli, 2023). This evidence concerns the gene MAPT and Brain atrophy.